Efficacy and safety of Xinfeng capsule in patients with rheumatoid arthritis: a multi-center parallel-group double-blind randomized controlled trial  by Jian, Liu et al.
JTCM |www. journaltcm. com October 15, 2015 |Volume 35 | Issue 5 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2015 October 15; 35(5): 487-498
info@journaltcm.com ISSN 0255-2922
© 2015 JTCM. All rights reserved.
CLINICAL STUDY
Efficacy and safety of Xinfeng capsule in patients with rheumatoid
arthritis: a multi-center parallel-group double-blind randomized
controlled trial
Liu Jian, Wang Yuan, Huang Chuanbing, Xu Jianhua, Li Zhijun, Xu Liang, He Liyun, Sun Yue, Wang Yali, Xu
Shengqian, Zhao Ping, Mao Tongjun, Tan Bin, Zhu Fubing, Zhang Pingheng, Fang Li
aa
Liu Jian, Wang Yuan, Huang Chuanbing, Sun Yue, Wang
Yali, Tan Bin, Zhu Fubing, Zhang Pingheng, Fang Li, De-
partment of Rheumatism Immunity, The First Affiliated Hos-
pital, Anhui University of Chinese Medicine, Hefei 230031,
China
Xu Jianhua, Xu Shengqian, Department of Rheumatism
Immunity, The First Affiliated Hospital of Anhui Medical Uni-
versity, Hefei 230022, China
Li Zhijun, Zhao Ping, Department of Rheumatism Immuni-
ty, The First Affiliated Hospital of Bengbu Medical College,
Bengbu 233004, China
Xu Liang, Mao Tongjun, Department of Rheumatism Im-
munity, The First Affiliated Hospital of Wannan Medical Col-
lege,Wuhu 241001, China
He Liyun, The Institute of Basic Research in Clinical Medi-
cine, China Academy of Chinese Medical Sciences, Beijing
100700, China
Supported by the Key Projects in the National Science &
Technology Pillar Program in the Twelfth Five-Year Plan Peri-
od: Clinical Research on Xin'an Medicine Prevention and
Treatment of Difficult Diseases of Chinese Medicine (No.
2012BAI26B02). ClinicalTrials.gov Identifier: NCT01774877
Correspondence to: Prof. Liu Jian, Department of Rheu-
matism Immunity, The First Affiliated Hospital, Anhui Univer-
sity of Chinese Medicine, Hefei 230031, China. liujianahzy@
126.com
Telephone: +86-13955109537
Accepted: September 9, 2015
Abstract
OBJECTIVE: To evaluate the efficacy and safety of
Xinfeng capsule in patients suffering rheumatoid
arthritis (RA).
METHODS: A multi-center parallel-group de-
signed, double-blind, randomized, controlled trial
was conducted. Totally 304 RA patients were as-
signed to two groups: one group was administered
Xinfeng capsule (XFC) plus the placebo of lefluno-
mide and the other given leflunomide (LEF) plus
the placebo of XFC for twelve weeks. The clinical
and laboratory parameters were compared at base-
line and fourth, eighth, and twelfth weeks.
RESULTS: After twelve-week treatment, patients in
two groups all showed some trend of effectiveness
when compared in terms of American Rheumatism
Association (ACR) recommended 20% , 50% , 70%
improvement criteria, but it was insignificant. The
validity in ameliorate modified disease activity
score (DAS28) and laboratory indexes as erythro-
cyte sedimentation rate (ESR), C-reactive protein
(CRP), rheumatoid factor (RF) were also found no
difference. The score of health assessment ques-
tionnaire (HAQ), self-rating anxiety scale (SAS),
self-rating depression scale (SDS) and quality of life
questionnaire with rheumatoid arthritis (RAQOL)
both lower than the first week and the changes
showed no difference. However, the score of SDS
dropped more in XFC group than in the other. A to-
tal of 147 adverse reaction cases were reported,
which shows no difference between the two
groups. The most common adverse reactions were
hepatic impairment, anemia, leukocytopenia, epi-
gastric discomfort and phalacrosis.
CONCLUSION: XFC demonstrated better improve-
ment in the scores of SDS and compared with
those of LEF group.
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease
which characteristically presents as a gradual symmetry,
multi-arthritis. There has associated loss of joints' func-
tion, 50%-90% patients will occur radiographic joint
destruction in the first 1 or 2 years.1 Although disease
activity may fluctuate, it will, if untreated, usually lead
to joint destruction with erosive cartilage and bone
damage, and potential tendon rupture.2 At the mean
time, RA is a multi-system disease, with the prevalence
of extra-articular manifestations estimated to occur in
up to 21.5% of patients with established disease,3 that as-
sociated with an unfavorable outcome. During the last
decade we have experience exciting developments re-
garding the approval of new treatment options, the ad-
vent of biological agents and disease-modifying an-
ti-rheumatic drugs (DMARDs) (including leflunomide,
methotrexate, sulfasalazine, azathioprine, et al) have
made a profound impact on the outcome and progno-
sis of RA4 In effect, DMARDs slow the disease process
by modifying the immune system in some way.
Leflunomide (LEF) is an oral immunomodulator
agent, which has been evaluated in RA in clinic and ex-
periment.5 Leflunomide is a competitive and reversible
inhibitor of the mitochondrial enzyme dihydroorotate
dehydrogenase restricting DNA and RNA synthesis in
activated lymphocytes by diminishing pyrimidine avail-
ability and preventing cells from entering the S phase
of the cell cycle. It can also inhibit protein tyrosine ki-
nases in proliferating T and B lymphocytes with a com-
mensurate decline in immunoglobulin synthesis.6
Recently, the traditional DMARDs still be recommend-
ed in the treatment of RA.7 The increasing cost of bio-
logics in this era of disease management led us to de-
vise a treatment regime, optimal for use in a develop-
ing country like China, which was economical as well
as effective in controlling disease activity.
LEF is one of immunosuppressants to cure RA in cur-
rent. It is that to inhibit dihydrogen orotic acid dehy-
drogenase activity to affect the pyrimidine nucleotide
synthesis pathway, and through inhibit tyrosine kinase
activity to restrain T cell activation signal transduction.
Its metabolites can affect the production of synovial fi-
broblasts of metalloproteinases, and it may inhibit the
nitric oxide synthesis of the body to achieve the immu-
noregulation effect. However, these available medica-
tions may not work for everyone. Some high prices
drugs make patients unable to long-term maintenance
treatment. Therefore, it still needs to study novel an-
ti-rheumatic drug.
Xinfeng capsule (XFC) as one of Chinese patent medi-
cine which produced by our hospital, has been widely
used in the clinical treatment of RA. XFC had been ap-
proved as a kind of hospital preparations by the Anhui
Province Food and Drug Administration in 1997, then
renamed the Fufangqiyi capsule in 2005 (drug approv-
al number: Anhui medicine system Z20050062). Drug
has good manufacturing practice and quality control.
The high-performance thin-layer chromatography
(HPTLC) fingerprint chromatographic for the evalua-
tion of XFC has shown in the previous study.8
Our preclinical studies showed that XFC have a defi-
nite effect on relieving symptoms of joins in RA pa-
tients.9-13 XFC can improve joint pain, swelling, and
early morning stiffness, and it can also improve ex-
tra-articular manifestations such as anemia, platelet dis-
ease, lipid metabolism disorder, cardiopulmonary func-
tion, depression and quality of life. In addition, there is
no adverse reaction of gastrointestinal disturbance and
hepatorenal function damage reported. Lab studies
have shown that14-19 XFC can reduce paw swelling and
AI of AA rats, and can improve the cardiopulmonary
function and behavior of AA rats. The possible mecha-
nism is the modulation of TGF-β1/Smads, Notch-Jag-
ged/Delta and several other signaling pathway in regu-
lating inflammatory/anti-inflammatory cytokines inter-
acting. Thus XFC can regulate the expression of T reg-
ulatory cell (Treg) and forkhead box P3 (Foxp3), re-
duce the deposition of immune complexes and reduce
the inflammatory reaction in tissue. These study data
supported that XFC deserve further research as a poten-
tial Chinese medicine compound preparation for RA
treatment. This clinical trial carried out simultaneously
in 4 clinical research centers, which conducted in a ran-
domized, double-blind, double parallel controlled
method. Chinese Academy of Traditional Chinese
Medicine was responsible for schema optimization,
quality control and outcome assessment.20 This study
reported the result after treatment for 12 consecutive
weeks, and described the clinical outcomes, efficiency,
and adverse reactions of XFC.
PATIENTS ANDMETHODS
Patients
Eligible patients should be ≥18 and ≤65 years old and
should have been diagnosed as active stage of RA based
on American Rheumatism Association (ACR) 1987 re-
vised criteria21 and classified into functional classⅠ, Ⅱ
or Ⅲ, according to Modified Disease Activity Score (3
variables) (DAS28-3)22 promulgated by the European
Union of anti-rheumatism. The disease activity of RA
patients and classification is judged by DAS28-3. Pa-
tients were excluded if they were taking corticosteroids
(≤ 15 mg prednisone or Equivalent) ≥ 4 weeks before
entering the trial or they have high disease activity
(DAS28-3 scores > 5.1) or they have diagnosed any
other chronic inflammatory disease or connective tis-
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sue disease like sjogren syndrome (SS), systemic lupus
erythematosus (SLE), etc. Patient who with sever dis-
eases in cardiovascular, brain, lung, liver, kidney and
hematopoietic system, or who is pregnant or nursing
mother or psychiatric patient, or whose white blood
cell count (WBC) ≤ 3.5 × 109/L, platelet is lower than
90 × 109/L, hemoglobin less than 8.5 g/dL, or who
have stomach troubles as gastric duodenal ulcer, gastri-
tis or long-term non-steroidal drugs, or who has
known hypersensitivity to trial medicine, or who has
participated in other clinical trials within 4 weeks of
screening, are rule out. Patients were recruited from 4
research centers in Anhui province, China. Followed
the ethical guidelines of the Declaration of Helsinki,
this study protocol was approved by the medical ethics
committee of the First Affiliated Hospital of Anhui
University of Chinese Medicine. Our hospital ethics
committee has obtained the certification by the Strate-
gic Initiative for Developing Capacity in Ethical Re-
view (SIDCER) of the world health organization in
2012.
Randomization
This research adopts the hierarchical block randomized
method. The Clinical Evaluation Center of CACMS
statistics personnel used SAS 9.1.3 statistical software
(SAS Institute Inc., Cary, NC, USA) PROC PLAN
program to randomize allocation, subjects were accept-
ed by the processing random arrangement, and divided
into four centers and two groups, which were named as
Xinfeng capsule group and leflunomide group. Con-
senting patients are according to the doctor order into
the groups. The implementation of the random scheme
used the central stochastic system.
Blinding
The patients, researchers, and data managers were
masked throughout this study.
Control
We had prepared the placebos for both XinFeng cap-
sule and leflunomide.
Multi-center
The trials were performed in the following hospitals:
The First Affiliated Hospital of Anhui University of
Chinese Medicine, The first Affiliated Hospital of
Bengbu Medical College, The first Affiliated Hospital
of Anhui Medical University, Yijishan Hospital of Wan-
nan Medical College.
Sample size
This trail is designed as a positive control superior trial
and intended to show the superiority of Chinese medi-
cine intervention. According to the previous literature,
The ACR20 effective rates of the control group were
62.54% 23 and the ACR20 effective rates of the XFC
were 79.23% based on previous researches and clinical
experiences, set α = 0.05 and test power 0.90, thus β =
1－0.9 = 0.10, The formula for sample size estimation
is as follows:25
n =(Ζα +Ζβ)2 ×(1 + 1k ) ×Ρ(1 -Ρ)/(Ρ1 -Ρ2)2
k means that the ratio of the two sample sizes which is
1∶1. Ρ means the mean of the the ACR20 effective
rates of the control group ( Ρ1 ) and the ACR20 effec-
tive rates of the Xinfeng Capsule ( Ρ2 ). Sample size
could be 127 in both groups. With a dropout rate for
follow-up as 20%, the sample size for each group could
be 152 and 304 in the two groups.
Intervention
Treatment group: Xinfeng capsule and placebo (for
leflunomide). Xinfeng capsule: Three each time, 3
times a day immediately after meals, oral, for 3
months; placebo (for leflunomide): 10 mg each time, 1
time a day immediately after meal, oral, for 3 months.
Control group: leflunomide & placebo (for Xinfeng
capsule). Leflunomide: 10 mg each time, one time a
day immediately after meal, oral, for 3 months, place-
bo (for Xinfeng capsule): three each time, 3 times a day
immediately after meals, oral, for 3 months. Xinfeng
capsule and its placebo were produced by the prepara-
tion department of the First Affiliated Hospital of An-
hui University of Chinese Medicine (Anhui pharma-
cists Certification Z20050062). Leflunomide and its
placebo were produced by Fujian Huitian Biological
Pharmacy Co., Ltd. (drug approval number:
H20050175, 10mg per pill). We will follow up partici-
pants at the 4th week after treatment by telephone,
and ask for conditions like joint pain, swelling, early
morning stiffness. The procedure is shown in Figur 1.
Measures
Clinical assessments of efficacy and safety measures
were obtained at baseline and at weeks 4, 8, and 12.
The Evaluation adopted the standard of an overall im-
provement in RA according to the American Rheuma-
tism Association (ACR) recommended in 2002,which
contained the following criteria: swollen joint count,
tender joint count, Health Assessment Questionnaire
(HAQ), C-reactive protein (CRP) level or erythrocyte
sedimentation rate (ESR), rest pain intensity assess-
ment and overall condition of patients which measured
on a visual analog scale(VAS) ranging from 0 mm (no
pain) to 100 mm (severe pain), and the VAS score will
be integrated by doctors. It is called ACR 20% im-
provement criteria (ACR20) when the first two criteria
reduced at least 20% and at least three of the remain-
ing improved 20% , which indicates effective. ACR50
and ACR70 represent clinical disease activity at least
50% or 70% improvement.
The primary efficacy end point was the proportion of
patients who had achieved the responses according to
the proportion of ACR20 at 12th week. The secondary
efficacy end points were the proportion of ACR50 and
ACR70 at 12th week.
Laboratory parameters includes: CRP, ESR, rheuma-
toid factor (RF), anti-cyclic citrullinated peptide anti-
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body (anti-CCP) antibodies, glucose-6-phosphate
isomerase (GPI), immune globulin (IgG, IgA, IgM),
d-dimer, and routine coagulation examinations.
Life quality assessments includes: Health assessment
questionnaire (HAQ), Quality of life questionnaire
with rheumatoid arthritis (RAQOL), Self-rating de-
pression scale (SDS) and Self-rating anxiety scale (SAS).
Syndrome comparison includes: total symptom inte-
gral, patient assessment of arthritis pain, the patient's
overall assessment of disease activity, physician's overall
assessment of disease activity, duration of morning stiff-
ness, the count of tender joint, the count of swollen
joint and Chinese medicine syndrome25 (including:
joint pain, night pain increased, joint swelling, fatigue,
reduce sodium food, joint flexion and extension nega-
tive, the degree of morning stiffness and joint tender-
ness degree, loose stool). Those clinical symptoms were
graded according to the severity of the disease and
quantified by four levels (0, 2, 4, 6 points).
The safety assessment includes physical examination
of basic vital signs and electrocardiogram (ECG) be-
fore the study and at 12-week intervals over the
course of the study. Liver and kidney function tests
were taken at baseline, 4th weeks, 8th weeks, and
12th weeks. Every visits were required a detailed re-
cord of all adverse events, including dizziness, head-
ache, itching, rash, hair loss, gastrointestinal symp-
toms, liver and kidney toxicity, leukopenia, and had
to record the time, severity, frequency, duration, the
measures taken and the outcome of adverse events.
The relationships between the adverse events of study
drug were assessed by the investigators. Serious ad-
verse events can be regarded when meeting the fol-
lowing conditions: require hospitalization, prolonged
hospitalization, disability, affecting the ability to
work, life-threatening or death, resulting in congeni-
tal malformations and other events.
Patients with RA
Excluded (n)
Eligible for criteria
Experimental group (n = 152)
Receive Xinfeng capsule &
placebo (for leflunomide)
Control group (n = 152)
Receive Xinfeng capsule &
placebo (for leflunomide)
Visit 1 (week 0, n = 152)
Outcome measures
Visit 1 (week 0, n = 152)
Outcome measures
Randomization of 304 Patients
Visit 2 (week 4, n = 152)
Outcome measures
Visit 3 (week 8, n = 152)
Outcome measures
Visit 2 (week 4, n = 152)
Outcome measures
Visit 3 (week 8, n = 152)
Outcome measures
Visit 4 (week 12,n=152)
Outcome measures
Visit 4 (week 12,n =152)
Outcome measures
Follow up (week 16,
n = 152) By telephone
Follow up (week 16,
n = 152) By telephone
Analyzed (n=152) Analyzed (n =152)
Figure 1 Procedure flow chart of the trail
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Statistical analysis
Measurement data between groups use t-test, Accord-
ing to figures characteristic features, χ2 test, t-test, Wil-
coxon rank test were performed. All statistical tests
were condected with two-tailed test and the difference
between the statistical tests was significant if P-value
less than or equal to 0.05.
RESULTS
Patient characteristics
A total of 304 patients were randomized into 2 groups,
including 282 cases who satisfied all protocol require-
ments, good compliance, completed the CRF, meet
the requirement of per protocol set (PPS) (treatment
group 139 cases, control group 143 cases). There was
no significant difference in dependence potential, vital
signs, medical history and diagnosis between two
groups on baseline. There was also no difference from
baseline on symptoms, like patient assessment of arthri-
tis pain, the patient's overall assessment of disease activ-
ity, physician's overall assessment of disease activity,
time and degree of morning stiffness, count of tender
joint, count of swollen joint, and the scores of symp-
toms as joint function. There was no significant differ-
ence in the number of swollen joints functional class,
DAS28-3 other groups close to the baseline PPS data
set. Thus the data of two groups are comparable (Ta-
ble 1).
Clinical efficacy
Main efficacy index ACR20 and secondary efficacy in-
dex ACR50, ACR70: after 12 weeks treatment, ACR
20% improvement criteria (ACR20) was 97.12% for
XFC treatment group, compared with 97.20% for the
LEF control group. For the criteria of ACR 50% im-
provement criteria (ACR50), the figures were 88.49%
and 82.52% , and the criteria of ACR 70% improve-
ment criteria (ACR70), the figures were 69.06% and
60.84% . There was no statistics difference between
two groups (P > 0.05). The results suggested that XFC
had comparable efficacy to Leflunomide (Table 2).
Disease activity indexes and laboratory indexes
After 12 weeks treatment, the disease activity index
DAS28-3, IgM, anti-CCP, thrombin time and and
D-dimer both showed a reduction compared with the
first week in XFC group (P < 0.05), while the level of
ESR, CRP, DAS28-3 and D-dimer decreased in LEF
group (P < 0.05). When compared between the two
groups, the disease activity index DAS28-3 and labora-
Item
Age (years)
Gender (male/female)
Duration (month)
Patients with arthritis pain assessment (mm)
Patient's overall assessment of disease activity (mm)
Morning stiffness (min)
Joint tenderness number (scores)
Joint swelling number (scores)
Joint function classification case [n(%)]
ClassⅠ
ClassⅡ
ClassⅢ
ClassⅣ
DAS28-3 (scores)
ESR (mm/h)
CRP (mg/L)
RF (IU/mL)
Anti-CCP (RU/mL)
GPI (mg/L)
Treatment group (n = 139)
47.8±10.4
17/122
59.4±67.1
58.8±14.8
58.1±14.3
72.5±47.6
5.1±2.3
4.2±2.7
-
6 (4.32)
86 (61.87)
47 (33.81)
0 (0.00)
4.6±0.5
35.4±25.1
18.8±26.2
138.2±156.4
242.6±265.0
1.5±7.0
Control group (n = 143)
48.9±10.5
27/116
61.8±65.6
57.8±17.4
57.5±17.4
67.9±38.3
4.7±2.1
3.7±2.1
-
9 (6.29)
99 (69.23)
34 (23.78)
1 (0.70)
4.6±0.6
40.5±28.1
19.9±25.0
145.4±181.5
267.2±277.5
1.6±6.7
F/Z/t/χ2 value
0.9100
-
－1.1414
－0.4900
－0.3200
0.4600
1.4239
1.5297
4.5441
-
-
-
-
0.1000
－1.3871
－0.3294
－0.1158
－1.2585
－0.5952
P value
0.3637
0.1239
0.2537
0.6239
0.7505
0.6455
0.1545
0.1261
0.2084
-
-
-
-
0.9190
0.1654
0.7419
0.9078
0.2082
0.5517
Notes: patients in the treatment group were administered Xinfeng capsule plus the placebo of leflunomide and control group given lefluno-
mide plus the placebo of Xinfeng capsule for twelve weeks. DAS28-3: modified disease activity score (3 variables); ESR: erythrocyte sedi-
mentation rate; CRP: C-reactive protein; RF: rheumatoid factor; Anti-CCP: anti-cyclic citrullinated peptide antibody; GPI: glu-
cose-6-phosphate isomerase.
Table 1 Patient population characteristics at baseline
491
JTCM |www. journaltcm. com October 15, 2015 |Volume 35 | Issue 5 |
Liu J et al. / Clinical Study
tory indexes, such as ESR, CRP, RF, et al, were found
no statistical significance in the first week and the
twelfth week, and also showed no significance in the
absolute value of the first week and twelfth week (P >
0.05). Only IgM has statistically significant difference
after 12 week treatments (P < 0.05, Table 3)
Quality of life
In the end of twelfth week, the score of HAQ, SAS,
SDS, RAQOL, and every domains of RAQOL both
lower than the first week in two groups (P < 0.01).
When compared between the two groups, the score of
HAQ, SAS, RAQOL, and every domains of RAQOL
were found no statistical significance in the first week
and twelfth week, and also showed no significance in
the absolute value of the first week and twelfth week
(P > 0.05). However, the score of SDS showed differ-
ence between two groups (34.71 ± 5.99 vs 36.41 ±
7.39, P = 0.035),and the absolute value of the first
week and twelfth week also statistically significant (P =
0.0163, Table 4).
Patient symptom integrals
In the end of twelfth week, the total scores of clinical
symptoms, which contains patient assessment of joint
pain, the patient's overall assessment of disease activity,
physician's overall assessment of disease activity, time
and degree of morning stiffness, count of tender joint,
count of swollen joint, and the scores of symptoms as
joint function, fatigue, poor appetite and loose stools
all decreased (P < 0.01). When compared between the
two groups, the improvement of total symptom inte-
gral, the count of tender joint , fatigue, poor appetite
in XFC group were superior to that in LEF group (P <
0.05), especially the symptom as pain aggravated in
night improved more effectively in XFC group (P <
0.01, Table 5).
Safety
During 12 weeks treatment process, a total of 147 ad-
verse reaction cases were reported. The incidence rate
in XFC group is 48.60%, and 51.40% in LEF group.
The rate of two groups, when compared by the Wilcox-
on rank-sum test (Z = 0.000, P = 1.000), shows no dif-
ference (P > 0.05). The most common adverse reac-
tions were hepatic impairment, anemia, leukocytope-
nia, epigastric discomfort and phalacrosis. However, no
severe adverse effect was encountered, and no exit of
enrollees due to adverse reactions (Table 6).
Item
4 weeks after
8 weeks after
12 weeks after
16 weeks after
ACR20
ACR50
ACR70
ACR20
ACR50
ACR70
ACR20
ACR50
ACR70
ACR20
ACR50
ACR70
Treatment group (n = 139)
103 (74.1)
39 (28.06)
16 (11.51)
130 (93.53)
94 (67.63)
47 (33.81)
135 (97.12)
123 (88.49)
96 (69.06)
135 (97.12)
129 (92.81)
102 (73.38)
Control group (n = 143)
101 (70.63)
40 (27.97)
15 (10.49)
128 (89.51)
87 (60.84)
44 (30.77)
139 (97.2)
118 (82.52)
87 (60.84)
134 (93.71)
125 (87.41)
96 (67.13)
P value
0.5147
0.9872
0.7840
0.2271
0.2347
0.5847
0.9675
0.1549
0.1479
0.1714
0.1300
1.3158
Notes: patients in the treatment group were administered Xinfeng capsule plus the placebo of leflunomide and control group given lefluno-
mide plus the placebo of Xinfeng capsule for twelve weeks. ACR20: American Rheumatism Association 20% improvement criteria when
the first two criteria reduced at least 20% and at least three of the remaining improved 20%, which indicates effective. ACR50 and ACR70
represent clinical disease activity at least 50% or 70% improvement.
Table 2 Patient responses according to the ACR RA improvement criteria [n (%)]
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DISCUSSIONIn order to provide more clinical medication for pa-
tients with RA, this clinical trials conduct in multi-cen-
ter randomized, double-blind, double parallel con-
trolled way for 12 weeks, using LEF as positive control
drug, that aim to an objective evaluation of the efficacy
and safety of XFC.
The advantages of XFC are more reflected on improve-
ments of SDS and syndrome. The main cause of emo-
tional disorders in RA patients prone to: disease brought
physiological function loss, anxiety and excessive worry
due to disease characteristics, which often manifest as
over sensitive, and adverse drug reaction. 27 Neuroendo-
crine-immune (NEI) network plays an important role
Indicator
DAS28-3 (scores)
ESR(mm/h)
CRP (mg/L)
RF (IU/mL)
IgA (g/L)
IgG (g/L)
IgM (g/L)
Anti-CCP (RU/mL)
GPI (mg/L)
Activated partial thromboplastin
time (s)
Plasma fibrinogen (g/L)
Thrombin time (s)
D-dimer (mg/L)
Time
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Week 1
Week 12
week12-week 1
Treatment group (n = 139)
4.57±0.54
4.00±3.57
－0.57±3.54
35.43±25.08
31.58±20.52
－4.00±19.72
18.83±26.21
13.99±17.58
－4.92±21.76
138.21±156.45
134.94±175.54
－1.81±120.76
2.92±1.72
2.99±1.89
0.06±1.83
15.01±4.64
14.60±4.82
－0.51±3.27
1.59±0.67
1.73±0.92
0.12±0.87
242.57±264.97
175.97±190.22
－34.82±216.91
1.54±7.01
2.22±10.01
－0.05±10.33
25.63±7.90
25.33±5.99
－0.29±6.36
3.83±2.28
5.90±25.45
2.19±26.32
17.98±3.64
17.44±2.69
－0.55±4.75
2.11±7.03
1.29±1.57
－0.91±7.25
Control group (n = 143)
4.57±0.62
3.61±0.86
－0.96±0.82
40.46±28.11
31.98±22.59
－8.28±25.57
19.89±25.02
12.89±20.62
－6.93±25.27
145.41±181.51
120.16±166.95
－23.19±105.91
3.01±1.35
3.00±1.45
0.01±0.64
15.56±4.45
15.15±4.17
－0.34±3.51
1.44±0.86
1.56±1.46
0.13±1.34
267.25±277.49
203.53±192.02
－39.15±243.09
1.63±6.67
0.93±1.11
－0.64±6.72
25.33±5.99
25.52±5.53
－1.05±7.20
3.70±0.99
3.92±2.42
0.25±2.43
17.57±2.92
17.57±2.92
0.10±4.34
1.84±2.14
1.43±1.75
－0.45±2.12
Z/t value
0.1000
－0.8051
－1.1761
－1.3871
0.2045
1.3407
－0.3294
1.3885
1.0902
－0.1158
0.7462
1.8829
－1.5709
－1.4100
0.1079
1.0200
1.0000
－0.6149
2.6524
3.1237
1.0008
－1.2585
－1.4701
－0.5569
－0.5952
0.0555
－0.0415
1.0500
0.2700
0.3662
－0.8351
－0.5706
－0.0305
－1.0200
0.3900
－1.6531
－1.2001
－0.7927
－0.4366
P value
0.9190
0.4208
0.2395
0.1654
0.8380
0.1800
0.7419
0.1650
0.2756
0.9078
0.4555
0.0597
0.1162
0.1585
0.9140
0.3090
0.3172
0.5386
0.0080
0.0018
0.3169
0.2082
0.1415
0.5776
0.5517
0.9558
0.9669
0.2947
0.7867
0.7142
0.4037
0.5683
0.9757
0.3095
0.6972
0.0983
0.2301
0.4280
0.6624
Table 3 Changes in disease activity index DAS28-3 and lab index in two groups after 12 weeks of treatment ( xˉ ± s)
Notes: patients in the treatment group were administered Xinfeng capsule plus the placebo of leflunomide and control group given lefluno-
mide plus the placebo of Xinfeng capsule for twelve weeks. DAS28-3: modified disease activity score (3 variables); ESR: erythrocyte sedi-
mentation rate; CRP: C-reactive protein; RF: rheumatoid factor; IgA: immune globulin A; IgG: immune globulin G; IgM: immune globu-
lin M; Anti-CCP: anti-cyclic citrullinated peptide antibody; GPI: glucose-6-phosphate isomerase.
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in pathogenesis of RA concomitant depression. RA
and depression has associated comorbidity basis on cy-
tokines and the change in hypothalamus-pituitary-adre-
nal axis-monoamine neurotransmitter system.28
SDS is a short self-administered questionnaire to quan-
tify the depressed status of a patient which was widely
used currently. It can be effectively used in a variety of
settings, which mainly indicate the effect on depression
emotion from diseases. The scores provide indicative
ranges for depression severity. The higher the score de-
clares the higher the level of depression. We also found
in previous studies that the SDS scores in RA patients
are positively associated with pain, obstacles in activi-
ties of daily living, work, house work, school, social
communications and the understanding of life in the
future. Meanwhile, the patient with a higher education-
al level showed fewer depressive symptoms, but the pa-
tient with a lower educational level or did more physi-
cal works showed more likely to be depression.29 Poor
psychological adjustment ability, discouragement and
isolation with no one else to turn to, and low income
can become the key reasons for depression.
Moreover, long-term use of glucocorticoids, used for
decades in the treatment of RA, are effective in slowing
radiographic progression by at least 50% when given
to patients with early RA,30 but can also cause sudden
Indicator
HAQ
SDS
SAS
RAQOL total score
RAQOL physiological function
domain
RAQOL social function domain
RAQOL psychological function
domain
RAQOL ability health domain
Time
Week 1
Week 12
12-1week
Week 1
Week 12
12-1 week
Week 1
Week 12
12-1 week
Week 1
Week 12
12-1 week
Week 1
Week 12
12-1 week
Week 1
Week 12
12-1 week
Week 1
Week 12
12-1 week
Week 1
Week 12
12-1 week
Treatment group (n = 139)
21.78±10.69
10.37±6.26
－11.41±10.93
43.61±9.60
34.71±5.99
－8.90±9.71
37.62±8.91
29.32±5.26
－8.30±9.29
79.34±17.68
59.88±13.11
－19.46±17.26
21.52±7.22
15.96±5.65
－5.56±6.51
21.98±5.23
18.20±4.20
－3.78±4.32
12.60±3.60
9.82±2.92
－2.78±3.48
23.54±5.18
17.83±4.33
－5.71±6.16
Control group (n = 143)
21.82±11.14
11.01±6.70
－10.81±10.70
42.97±10.34
36.41±7.39
－6.56±10.48
37.34±9.06
30.43±6.31
－6.91±9.93
79.66±18.54
62.04±13.33
－17.62±17.86
21.55±7.56
16.20±5.32
－5.35±6.98
21.91±4.78
17.60±3.94
－4.31±4.02
12.47±3.50
9.37±2.61
－3.11±3.41
23.44±5.21
16.96±4.01
－6.48±5.85
Z/t value
－0.0650
－0.7855
－0.3143
－0.5400
2.1200
－2.4022
－0.2600
－1.6100
－1.3526
0.1500
1.3700
－0.9935
0.0300
0.3700
－0.3994
0.1200
1.2500
－0.9904
0.3000
1.3700
－0.9795
0.1600
1.7500
－1.1903
P value
0.9482
0.4321
0.7533
0.5912
0.0350
0.0163
0.7967
0.1080
0.1762
0.8800
0.1704
0.3205
0.9751
0.7148
0.6896
0.9033
0.2127
0.3220
0.7651
0.1726
0.3273
0.8723
0.0819
0.2339
Notes: patients in the treatment group were administered Xinfeng capsule plus the placebo of leflunomide and control group given lefluno-
mide plus the placebo of Xinfeng capsule for twelve weeks. HAQ: health assessment questionnaire; SDS: self-rating depression scale; SAS:
self-rating anxiety scale; RAQOL: quality of life questionnaire with rheumatoid arthritis.
Table 4 Changes in patients life quality scores in two groups after 12 weeks of treatment (scores, xˉ ± s)
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Symptom
Symptom score (scores)
Number of joint tenderness
Joint swelling number
Tired weakness (scores)
eat less (scores)
Stool thin pond (scores)
Patient assessment of joint pain
(scores)
Patients' overall assessment of
disease activity (scores)
Physician's overall assessment of
disease activity (scores)
Morning stiffness time (min)
The degree of joint pain (scores)
Night pain worse (scores)
Time
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Treatment group (n = 139)
17.11±5.89
13.04±4.68
9.71±3.72
6.40±3.71
5.08±2.27
4.44±2.08
3.24±1.86
1.87±1.71
4.19±2.69
3.10±2.32
2.06±1.91
1.06±1.70
2.47±1.26
1.70±1.23
1.15±1.08
0.52±0.88
1.73±1.37
1.15±1.23
0.59±0.95
0.12±0.47
0.38±0.53
0.28±0.14
0.17±0.38
0.06±0.23
58.80±14.79
49.42±13.61
39.47±14.59
29.09±17.31
58.14±14.31
48.90±13.49
39.19±14.57
28.78±17.17
58.14±14.31
48.90±13.49
39.19±14.57
28.78±17.17
72.48±47.56
47.58±34.55
33.14±29.05
18.81±23.41
3.09±1.21
2.42±0.82
2.10±0.44
1.93±0.51
2.46±1.39
1.86±1.12
1.29±1.10
0.65±1.00
Control group (n = 143)
16.75±5.89
12.85±4.74
9.94±4.09
7.53±4.30
4.70±2.10
4.02±2.01
3.22±1.78
2.31±1.48
3.66±2.11
2.73±1.74
1.92±1.62
1.16±1.41
2.34±1.44
1.90±1.26
1.31±1.19
0.88±1.13
1.62±1.50
0.92±1.18
0.55±1.01
0.42±0.94
0.30±0.52
0.22±0.41
0.20±0.42
0.17±0.42
57.85±17.41
48.36±14.72
41.16±14.76
32.08±15.71
57.53±17.42
47.75±14.17
40.69±14.36
31.69±15.73
57.53±17.42
47.75±14.17
40.69±14.36
31.69±15.73
67.92±38.34
48.59±27.59
33.15±23.46
21.75±19.97
3.17±1.15
2.55±0.95
2.18±0.71
2.01±0.56
2.38±1.50
1.76±1.22
1.27±1.18
0.73±0.99
Z value
0.5253
0.4440
－0.2759
－2.1532
1.4239
1.8345
－0.3238
－2.9658
1.5297
0.9386
0.2393
－1.6670
1.0024
－1.2702
－1.0312
－2.7549
1.2874
2.1433
0.8731
－2.9427
1.4845
1.1321
1.2775
－1.6422
－0.4900
－0.6200
0.9700
－1.4830
－0.3200
－0.8800
0.8700
－1.5148
－0.3200
－0.8800
0.8700
－1.5148
0.4600
0.2700
－0.3579
－1.9145
－0.7426
－1.1678
－1.0579
－1.3476
0.4882
0.7459
0.2934
－0.7851
P value
0.5994
0.6571
0.7827
0.0313
0.1545
0.0666
0.7461
0.0030
0.1261
0.3479
0.8100
0.0955
0.3161
0.2040
0.3024
0.0059
0.1980
0.0321
0.3826
0.0033
0.1377
0.2576
0.2014
0.1006
0.6239
0.5334
0.3336
0.1381
0.7505
0.3792
0.3852
0.1298
0.7505
0.3792
0.3852
0.1298
0.6455
0.7857
0.7204
0.0556
0.4577
0.2429
0.2901
0.1778
0.6254
0.4557
0.7692
0.4324
Table 5 Changes in patient symptom integrals in two groups after 12 weeks of treatment ( xˉ ± s)
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weight gain, truncal fat deposition, swelling of the face
as rounded 'moon face', increased skin fragility, and al-
opecia.31 Those side-effects may lead to unestimated
mental impairment on self-image and self-esteem of pa-
tients. Therefore, when choose or evaluate curative ef-
fect of a treatment, we should not only focus on the
short-term efficacy, but also investigate more on the
profound impacts of the treatment from a socio-psy-
chological angle. We should attend to help the patients
to adjust and shift gears, to set up the correct under-
standing, and to enhance the quality of life, hence im-
proving the long-term curative effect.
The improvement of total symptom integral, the count
of tender joint, fatigue, poor appetite in XFC group
were superior to that in LEF group, especially the
symptom as pain aggravated in night improved more
effectively in XFC group. That convinced that XFC
can not only improve the function of joints, but also
can improve the body's overall functional status. XFC
consisted of four raw herbs, which were astragalus,
myotonin, thunder god vine, and centipede. The mod-
ern pharmacology research thought that astragalus has
an anti-inflammatory effect, which can inhibit the gen-
eration of inflammatory mediators, like IL-8, TNF-α,
NO, suppress the generation of free radicals, and can
facilitate the expression of glucocorticoid receptors in
inflammatory cells.32 Myotonin has effects of anti-in-
flammation and anti-immunity, which can regulate the
immuno-functions through NF-kB and protein kinase
C pathway.33 Thunder god vine has effects on inflam-
mation and immunity, also can improve microcircula-
tion, often used for treating rheumatological diseases.34
Centipede can effectively mixed the expression of
pro-inflammatory and anti-inflammatory cytokines in
good, balanced proportions thus can relieve or prevent
synovitis consequently.35
The incidence rate of adverse reaction shows no differ-
ence between the two groups over the entire study peri-
od, and the adverse reaction is moderate, have no ef-
fect on trail process. However, digestive tract symp-
toms as epigastric discomfort were more common to
be seen in LEF group, is remarkable. At the same time,
occurs of fatigue, poor appetite and loose stools de-
creased in XFC group, which indicates XFC has fewer
digestive tract when improving symptom.
Although, this trail still have many limitations. Larger
and longer scale studies should further explore the con-
current use of XFC and should delve further into the
details of the specific herbs and active pharmaceutical
ingredients, patterns of use, as well as clinical observa-
tions of possible anti-rheumatic drug interactions and
herb-related toxicities. In our experience, XFC is a
safe, effective, low-cost intervention that can be used
to cure patients more present and mindful. But some
Symptom
Joint swelling degree (scores)
Adverse joint flexion and
extension (scores)
Morning stiffness degree (scores)
Time
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Week 1
Week 4
Week 8
Week12
Treatment group (n = 139)
2.53±1.22
2.03±0.99
1.61±0.96
0.94±1.08
1.28±0.61
1.14±0.49
0.85±0.43
0.69±0.55
1.68±0.76
1.34±0.68
1.00±0.54
0.81±0.60
Control group (n = 143)
2.52±1.11
1.97±0.95
1.65±0.90
1.08±1.08
1.27±0.57
1.07±0.48
0.90±0.40
0.69±0.51
1.72±0.66
1.36±0.63
1.05±0.52
0.88±0.52
Z value
0.0149
0.5062
－0.3906
－1.1561
0.1116
1.3122
－1.0835
－0.0293
－0.5059
－0.4758
－0.7553
－1.4105
P value
0.9881
0.6127
0.6961
0.2477
0.9111
0.1895
0.2786
0.9766
0.6129
0.6342
0.4501
0.1584
Table 5 Changes in patient symptom integrals in two groups after 12 weeks of treatment ( xˉ ± s) (continued)
Note: patients in the treatment group were administered Xinfeng capsule plus the placebo of leflunomide and control group given lefluno-
mide plus the placebo of Xinfeng capsule for twelve weeks.
Statistic
The number of cases of adverse event
Cases of adverse event [n (%)]
Mild [n (%)]
Moderate [n (%)]
Severe [n (%)]
Total (n)
Incidence (%)
Treatment group
44 (84.62)
8 (15.38)
0 (0.00)
52
48.60
73 (49.66)
Control group
49 (89.09)
6 (10.91)
0 (0.00)
55
51.40
74 (50.34)
In total
93
14
0
107
100.00
147
Table 6 Adverse reaction in two groups
Note: patients in the treatment group were administered Xinfeng capsule plus the placebo of leflunomide and control group given lefluno-
mide plus the placebo of Xinfeng capsule for twelve weeks.
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adverse events occur in this trail that can be the focus
of much research. Further research should also address
patients' education. Multiple subjective factors influ-
ence the outcome of therapy.
In conclusion, the results of this clinical trail indicate
that XFC therapy 9 pills/day was as effective as LEF
therapy 10 mg/day in 12 weeks and represents a new
superiority in improving the score of SDS and scores of
symptoms than LEF, which suggests that XFC might
be an altanertive to the treatment of RA. Although we
still have to pay more attention to the potential adverse
reactions of XFC, such as liver-enzyme abnormalities,
leukocytopenia, etc. The long-term efficacy of XFC on
protecting bone from destruction still needs to be fur-
ther investigated.
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